Antidepressant withdrawal is common, and may be severe in about half of those who experience it. Indeed, in 2019, England’s National Institute for Health and Care Excellence (NICE) updated their guidelines to acknowledge the potential for severe and long-lasting antidepressant withdrawal. However, it’s difficult to predict who will experience withdrawal.
Now, researchers have conducted a review of the existing data in order to try to answer this question: What factors increase the risk of withdrawal after stopping antidepressants?
Their answer: duration of use is a major factor, with people who have used the drug for years at the risk. Another important predictor is whether people experience withdrawal from the drug before—either after forgetting a dose, or after trying to stop before.
Other predictors include the specific antidepressant used and the dose of the drug.
Using the predictors they identified, the researchers then created a table which can be used to identify patients at higher risk of withdrawal. Patients with a higher risk score may want to be the most careful when it comes to slowly tapering off the drug.
The researchers suggest that future work needs to be done to confirm and refine the predictive ability of these factors.
The article was a review of nine previous studies that had included data on withdrawal effects. One of the studies was conducted by the Committee on the Safety of Medicines (CSM), which was able to obtain and analyze unpublished data from drug manufacturers. This is useful since published data is more likely to be favorable to the industry.
The researchers write that “in its severe form, the SSRI withdrawal syndrome has been reported to be associated with ataxia leading to falls, electric shock sensations that impair walking and driving, and urgent consultations at emergency departments, in published case studies. The discontinuation period is also associated with a 60% relative increase in suicide attempts, compared with previous users of antidepressants.”
What causes withdrawal symptoms? According to the researchers, antidepressants perturb brain chemistry, and the brain adapts to these changes to maintain homeostasis. For instance, since SSRIs cause more serotonin to remain in the synaptic cleft, the brain compensates by producing less serotonin. When the drug is stopped, the brain changes persist until it can adapt to the new, drug-free state.
This biological adaptation is called dependence, which the researchers are careful to note is different from addiction. Addiction involves cravings, compulsive use, and other psychological effects that do not seem to be present with antidepressants.
“Adaptations to the presence of the drug predict withdrawal effects because these adaptations do not resolve instantly upon stopping the drugs but will persist for some period: the ‘mis-match’ between the level of drug action to which the body has been adapted to and the lesser amount of drug action it receives (upon dose reduction or cessation) gives rise to withdrawal effects,” the researchers write.
Interestingly, perhaps because of its longer half-life, they found fluoxetine (Prozac) to be less likely than other antidepressants to cause withdrawal symptoms, while paroxetine (Paxil, which has a short half-life) was associated with the highest risk. However, it is also possible that fluoxetine (with its longer half-life) may cause delayed withdrawal symptoms that were not picked up in short-term trials.
SNRIs and MAOIs were also associated with the highest risk, possibly because they affect different and more varied brain systems.
One factor that was not associated with a level of risk: the psychiatric diagnosis. That is, it doesn’t seem to matter for what reason you were prescribed an antidepressant when predicting whether you might experience withdrawal.
Higher doses of antidepressant were associated to some extent with increased risk of withdrawal, but this was a less significant factor than the others. The researchers theorize that this “ceiling effect” may be due to the hyperbolic dose-response curve of the drugs. Even the lowest “clinical” dose of an antidepressant already occupies almost all serotonin receptors, meaning that increasing the dose doesn’t make much difference neurobiologically.
The article was published in the journal CNS Drugs. The researchers included Mark Horowitz, Adele Framer, Michael P. Hengartner, Anders Sørensen, and David Taylor.
Horowitz was interviewed by Mad in America in 2019, discussing a paper in lancet Psychiatry, co-written with Taylor, who reviewed the evidence for very slow tapering for antidepressant discontinuation in order to avoid withdrawal effects. Horowitz also explained that he came to this realization after attempting to withdraw from antidepressants himself and discovering withdrawal symptoms first hand.
Framer, also known by her online handle of Altostrata, founded the peer support website SurvivingAntidepressants.org after her own experience attempting to withdraw from paroxetine. She has also been interviewed by Mad in America.
Hengartner is the author of a recent book, Evidence-biased Antidepressant Prescription, Overmedicalisation, Flawed Research, and Conflicts of Interest, which explores the ways financial conflicts of interest have distorted and compromised the scientific literature when it comes to the efficacy and safety of antidepressants. He has also been interviewed by Mad in America.
Anders Sørenson is a Danish clinical psychologist who has also been interviewed by Mad in America about his work around antidepressant drug withdrawal.
Taylor, a frequent co-author of the others, is a renowned researcher on these topics who has been involved in the NICE guidelines and in the Maudsley Prescribing Guidelines as well.
Horowitz, MA, Framer, A., Hengartner, MP, Sørensen, A., & Taylor, D. (2022). Estimating risk of antidepressant withdrawal from a review of published data. CNS Drugs. Published online on December 14, 2022. https://doi.org/10.1007/s40263-022-00960-y [Full text]